PT-141 (bremelanotide) holds a distinction unique in the research peptide space: it's the only peptide approved by the FDA for sexual dysfunction. Marketed as Vyleesi, it received FDA approval in June 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women — making it a prescription drug with defined clinical trial data, not a grey-market research compound. That regulatory status changes how you access it, what quality guarantees you have, and what questions your prescriber should be answering (FDA, Vyleesi label, 2019).
The complication for many buyers is that Vyleesi's approval is specifically for premenopausal women with HSDD — it's not approved for men, and it's not approved for situational use or performance enhancement. Off-label prescribing for men is legal but unsupported by FDA-reviewed efficacy data. Understanding which situation you're in determines which access pathway is appropriate.
Key Takeaways
- —PT-141 (bremelanotide) is FDA-approved as Vyleesi for HSDD in premenopausal women — a prescription drug, not a research compound. Qualifying patients pay $0 for a 4-dose starter box via Palatin's patient program.
- —The mechanism is central: MC4R (melanocortin-4 receptor) activation in the brain — fundamentally different from PDE5 inhibitors (sildenafil, tadalafil) which act peripherally on blood flow.
- —Off-label prescribing for men is legal under physician discretion; no FDA-reviewed RCT supports this use, but there is Phase II data.
- —Research-grade PT-141 from unregulated vendors has no quality oversight — the FDA-approved route is accessible and often free or low-cost for women with HSDD.
PT-141 is a cyclic heptapeptide with molecular weight 1025.18 Da, derived from Melanotan II. Its full chemical name is bremelanotide. The mechanism that distinguishes it from every other sexual dysfunction treatment is where it acts: the central nervous system, specifically via melanocortin-4 receptor (MC4R) activation in the hypothalamus.
Sildenafil (Viagra), tadalafil (Cialis), and other PDE5 inhibitors act peripherally — they enhance blood flow to genital tissue by inhibiting phosphodiesterase-5, which relaxes smooth muscle. They require sexual stimulation to work. PT-141 doesn't enhance blood flow directly. It modulates dopaminergic pathways in the brain to increase sexual desire — the motivation component rather than the vascular component. This is why it was studied in women (where desire disorder is often the primary dysfunction) and why it produces different effects than PDE5 inhibitors in both sexes.
There are three distinct pathways, each with different quality and cost implications.
1. FDA-approved Vyleesi (premenopausal women with HSDD). This is the only route with full regulatory quality assurance. The product is manufactured under GMP standards, dispensed through licensed pharmacies, and backed by Phase III clinical trial data. Palatin Technologies (the manufacturer) runs a patient assistance program — commercially insured patients who meet the HSDD diagnosis criteria pay $0 for their first 4-dose box. Subsequent boxes are available at reduced cost via the savings programme. This is not widely advertised, which means many eligible patients are paying out of pocket when they don't need to.
2. Telehealth prescription — off-label (for men, or postmenopausal women). PT-141 is not approved for men or for women past menopause, but off-label prescribing under physician judgment is legal. Several telehealth platforms prescribe bremelanotide for men with erectile dysfunction who haven't responded to PDE5 inhibitors, or for whom PDE5 inhibitors are contraindicated. The product dispensed through this route would either be brand-name Vyleesi or a compounded bremelanotide from a 503A pharmacy — both require a valid prescription.
3. Research-grade PT-141 from unregulated vendors. This is the grey-market route — no prescription, no physician oversight, no pharmaceutical quality controls. The compound exists in the same regulatory grey zone as other unscheduled research peptides. Quality verification requires the same HPLC + MS framework as any other research peptide. MW 1025.18 Da is the mass spectrometry confirmation target.
For women with HSDD, the evidence is clear enough that the FDA approved the compound. The Phase III RECONNECT trial showed statistically significant improvements in the Female Sexual Function Index (FSFI) desire domain and Female Sexual Distress Scale-Desire (FSDS-DAO) scores compared to placebo over the 24-week trial. Mean increase in satisfying sexual events was the primary endpoint — and the drug cleared it.
For men, the picture is different. There is Phase II data showing bremelanotide improved erectile function scores in men with erectile dysfunction, including those who hadn't responded to sildenafil. But no Phase III RCT in men has been published. The off-label male use is built on that Phase II signal plus the mechanistic logic that MC4R activation is not sex-specific at the receptor level.
The full PT-141 research profile on Next Pep covers the complete MC4R mechanism, the RECONNECT trial data, the PDE5 comparison, and the Phase II male data honestly. That's the right starting point before you engage any prescriber or vendor.
If you're using the research peptide route — not the recommended path for most use cases — the quality verification framework applies:
HPLC purity ≥98%. Standard research-grade minimum. MS at 1025.18 Da. Confirms bremelanotide identity. Third-party COA with verifiable lot number. Standard for all research peptides — the report ID must resolve on the issuing lab's server. Lyophilised form. PT-141 degrades in solution. White or off-white powder only.
One additional check: PT-141 is typically reconstituted in bacteriostatic water to 10 mg/mL and used in doses of 1.75 mg (the clinical dose used in the RECONNECT trial). Vendors suggesting doses significantly above 2 mg are recommending more than the Phase III protocol — that's worth noting when evaluating their marketing.
The detailed PT-141 research guide covers everything you need to understand the MC4R mechanism, the RECONNECT trial data, the PDE5 comparison, and the Phase II male use evidence before approaching a prescriber or vendor. The peptide library gives you PT-141's full molecular profile — MW 1025.18 Da, amino acid sequence, pharmacokinetics, and regulatory summary — in one cross-referenced view.
If you're comparing PT-141 against other compounds for the same application, the comparison tool lets you examine mechanism differences side by side — without relying on vendor descriptions that have a financial interest in your purchase decision. For any injectable protocol, the dosing calculator handles the reconstitution: enter your vial concentration (typically 10 mg/mL) and target dose to get exact draw volume and syringe units. Next Pep is the neutral starting point. Use it before you speak to anyone selling something.
Yes — Vyleesi is the brand name for bremelanotide (PT-141), the FDA-approved subcutaneous injection for HSDD in premenopausal women. The peptide sequence is identical. The difference is that Vyleesi is manufactured under GMP pharmaceutical standards, dispensed through licensed pharmacies with a prescription, and backed by Phase III clinical trial data. Research-grade PT-141 from unregulated vendors has none of those quality guarantees.
Qualifying premenopausal women with HSDD who are commercially insured can receive their first 4-dose box of Vyleesi at $0 through Palatin's patient savings programme. Subsequent boxes are available at reduced cost. Without insurance, Vyleesi carries a list price that varies by pharmacy. Off-label compounded bremelanotide through a telehealth platform is typically $100–200 per course. Research-grade PT-141 varies widely — price alone is not a quality indicator.
PT-141 is not FDA-approved for use in men. However, a licensed physician can prescribe it off-label at their discretion — this is legal under the Federal Food, Drug, and Cosmetic Act. The physician prescribing off-label assumes responsibility for the clinical decision. The evidence supporting male use is Phase II (not Phase III), which means the evidence base is weaker than for the approved female HSDD indication.
The FDA-approved dose of Vyleesi is 1.75 mg subcutaneous injection, administered approximately 45 minutes before anticipated sexual activity. No more than one dose per 24 hours; no more than one dose per week. The RECONNECT Phase III trial used this dose. Doses used in research vendor contexts sometimes differ — be aware that doses significantly above 1.75 mg are outside the tested clinical protocol range.
This article is for informational purposes only. Vyleesi (bremelanotide) is an FDA-approved prescription medication for HSDD in premenopausal women. Off-label use requires a licensed physician's prescription. PT-141 from research vendors has no regulatory quality oversight. Consult a qualified healthcare professional.
Research Disclaimer. All content on Next Pep is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Consult a licensed healthcare professional before considering any peptide protocol.
A head-to-head comparison of BPC-157 and TB-500 covering mechanism, tissue specificity, dosing frequency, human evidence, and whether stacking them adds anything the literature actually supports.
Ipamorelin is a ghrelin-receptor agonist; CJC-1295 is a GHRH analog. Their mechanisms are complementary, which is why protocols typically stack them. This guide covers what each does alone, what stacking adds, and the DAC vs non-DAC distinction.